Brown Brothers Harriman & Co’s Acceleron Pharma XLRN Stock Holding History

Brown Brothers Harriman & Co’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,000	Closed	-$688	–	1237
2021 Q3	$688	Hold	4,000	–	–	﹤0.01%	277
2021 Q2	$502	Hold	4,000	–	–	﹤0.01%	320
2021 Q1	$542	Hold	4,000	–	–	﹤0.01%	288
2020 Q4	$512K	Buy	+4,000	New	+$469K	﹤0.01%	296
2017 Q1	–	Sell	-71	Closed	-$2K	–	907
2016 Q4	$2K	Hold	71	–	–	﹤0.01%	838
2016 Q3	$3K	Sell	71 -400	-85%	-$13.3K	﹤0.01%	736
2016 Q2	$16K	Buy	+471	New	+$15.3K	﹤0.01%	585

Brown Brothers Harriman & Co's XLRN Position: Q4 2021 in Review

Brown Brothers Harriman & Co sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 4,000 shares — an estimated $688 sold.

Brown Brothers Harriman & Co first reported a position in XLRN in Q2 2016 and held it in 7 quarters. The position peaked at $512K in Q4 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Brown Brothers Harriman & Co reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Brown Brothers Harriman & Co sold 4,000 Acceleron Pharma shares in Q4 2021, an estimated $688.
Brown Brothers Harriman & Co first reported a position in Acceleron Pharma in Q2 2016 and held it in 7 quarters.
Brown Brothers Harriman & Co's Acceleron Pharma position peaked at $512K in Q4 2020.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Brown Brothers Harriman & Co's 13F filing for Q4 2021, filed 14 Feb 2022.